Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
December 05 2016 - 4:01PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the
Company has hired Theresa LaVallee, Ph.D., to the newly created
position of Senior Vice President, Regulatory and Precision
Medicine. Dr. LaVallee was previously Senior Vice President,
Translational Medicine and Product Development at Kolltan
Pharmaceuticals, which Celldex recently acquired. Dr. LaVallee
brings more than 15 years of industry experience in discovery and
development of drug candidates in oncology and inflammation,
including extensive global regulatory experience and expertise in
translational medicine to enable science-driven drug development.
"Dr. LaVallee played a critical role in developing and advancing
the pipeline at Kolltan Pharmaceuticals, and we felt it was
important to bring her expertise in-house to Celldex,” said Anthony
Marucci, Co-founder, President and Chief Executive Officer of
Celldex Therapeutics. "In her new role, Theresa will continue to
provide leadership to the receptor tyrosine kinase programs but
will also reinforce our efforts in targeted drug development by
assuming the leadership function for our precision medicine and
regulatory activities. We believe Theresa is a valuable addition to
our team and look forward to working with her.”
"Celldex has been at the forefront of the precision medicine
field, identifying specific disease-related markers and developing
targeted therapeutics to meet the needs of these distinct patient
groups,” said Theresa LaVallee, Ph.D., Senior Vice President,
Regulatory and Precision Medicine. “While these initiatives combine
the best of science—biomarker discovery, companion diagnostics and
drug development—they also bring an increasing level of complexity,
especially from a regulatory perspective. I look forward to working
with Celldex to navigate these complexities and improve outcomes
for patients.”
Dr. LaVallee joined Kolltan in 2013, most recently serving as
Senior Vice President, Translational Medicine and Product
Development, and was responsible for developing and executing the
research and development strategy. She established and expanded the
Company’s translational medicine, project management and
development capabilities to transition Kolltan from a preclinical
to clinical stage company, including leading the regulatory
strategy behind these programs. Prior to Kolltan, Dr. LaVallee held
increasingly senior level roles at MedImmune/AstraZeneca and
EntreMed. Dr. LaVallee started her career as a research scientist
and has published extensively on her work throughout her career.
She received her Ph.D. in Microbiology and Molecular Genetics from
the University of California, Los Angeles.
About Celldex Therapeutics, Inc.Celldex is
developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline is
built from a proprietary portfolio of antibodies and
immunomodulators used alone and in strategic combinations to create
novel, disease-specific therapies that induce, enhance or suppress
the body's immune response. Visit www.celldex.com.
Forward Looking StatementThis release contains
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including those related to the Company's strategic focus and the
future development and commercialization (by Celldex and others) of
glembatumumab vedotin ("glemba"; CDX-011), varlilumab ("varli";
CDX-1127) and other products and our goals for 2016.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct or that those goals
will be achieved, and you should be aware that actual results could
differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to successfully complete research and further development and
commercialization of glembatumumab vedotin and other drug
candidates; our ability to obtain additional capital to meet our
long-term liquidity needs on acceptable terms, or at all, including
the additional capital which will be necessary to complete the
clinical trials that we have initiated or plan to initiate; our
ability to successfully integrate our and Kolltan’s business and to
operate the combined businesses efficiently; our ability to realize
the anticipated benefits from the acquisition of Kolltan; the
uncertainties inherent in clinical testing and accruing patients
for clinical trials; our limited experience in bringing programs
through Phase 3 clinical trials; our ability to manage and
successfully complete multiple clinical trials and the research and
development efforts for our multiple products at varying stages of
development; the availability, cost, delivery and quality of
clinical and commercial grade materials produced by our own
manufacturing facility or supplied by contract manufacturers, who
may be our sole source of supply; the timing, cost and uncertainty
of obtaining regulatory approvals; our ability to maintain and
derive benefit from the Fast Track designation for glembatumumab
vedotin which does not change the standards for regulatory approval
or guarantee regulatory approval on an expedited basis, or at all;
the failure of the market for the Company's programs to continue to
develop; our ability to protect the Company's intellectual
property; the loss of any executive officers or key personnel or
consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company's products;
and other factors listed under "Risk Factors" in our annual report
on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Associate Director of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Media Inquiries
Dan Budwick
BrewLife
(973) 271-6085
dbudwick@brewlife.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Sep 2023 to Sep 2024